DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight’s comprehensive HER2 Positive Breast Cancer Pipeline Report @ https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight
Key Takeaways from the HER2 Positive Breast Cancer Pipeline Report
- On July 02, 2026- Jazz Pharmaceuticals initiated a phase 2 study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer.
- On July 02, 2026- Jules Bordet Institute conducted a phase II study that will enroll subjects with HER2-positive advanced/metastatic breast cancer (mBC) who have experienced disease progression under trastuzumab deruxtecan (T-DXd) in the metastatic setting.
- DelveInsight’s HER2 Positive Breast Cancer Pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for HER2 Positive Breast Cancer treatment.
- The leading HER2 Positive Breast Cancer Companies such as BioNTech, Innovent Biologics, Shanghai Henlius Biotech, Eisai Co., Ltd., Bliss Biopharmaceutical (Hangzhou) Co., Ltd., EMUXA Biotechnology, CSPC ZhongQi Pharmaceutical Technology, Johnson and Johnson, Novartis Pharmaceuticals, F. Hoffmann-La Roche Ltd, Novartis AG, Jiangsu HengRui Medicine Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Jazz Pharmaceuticals, Inc., Zymeworks Inc., Enliven Therapeutics, Mersana Therapeutics, Iambic Therapeutics, Inc., Alteogen, Inc., and GeneQuantum Healthcare (Suzhou) Co., Ltd and others.
- Promising HER2 Positive Breast Cancer Pipeline Therapies such as Trastuzumab, Paclitaxel, Zanidatamab, Letrozole, Tamoxifen, PTC+Pertuzumab, FEC-T+Pertuzumab, SHR-A1811, Pyrotinib and others.
Access DelveInsight’s in-depth HER2 Positive Breast Cancer Pipeline Analysis for a closer look at promising breakthroughs @ HER2 Positive Breast Cancer Clinical Trials and Studies
HER2 Positive Breast Cancer Overview
HER2-Positive Breast Cancer is an aggressive subtype characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2), a protein involved in regulating cell growth and survival. It accounts for approximately 15–20% of all breast cancer cases and is associated with rapid tumor growth, higher recurrence rates, and poorer prognosis. HER2 overexpression activates key signaling pathways such as PI3K/AKT and MAPK, leading to uncontrolled cell proliferation and tumor progression. Diagnosis is typically confirmed using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).The cause of HER2-positive breast cancer is mainly linked to amplification of the HER2 gene, leading to overproduction of the HER2 protein and continuous activation of cell growth signals. According to the National Center for Biotechnology Information, this results in uncontrolled cell proliferation and tumor development. The condition is usually sporadic, caused by acquired genetic changes rather than inherited mutations, although factors like age and hormonal influences may contribute.
HER2 Positive Breast Cancer Emerging Drugs Profile
- Trastuzumab pamirtecan (BNT-323): BioNTech
Trastuzumab pamirtecan (BNT-323) is a third-generation topoisomerase-1 inhibitor-based ADC that specifically targets HER2. The drug is composed of a HER2-targeting antibody conjugated to a topoisomerase-1 inhibitor payload. This mechanism of action allows for the selective delivery of a cytotoxic agent to cancer cells expressing the HER2 protein, thereby minimizing systemic toxicity to healthy tissues. The efficacy of this targeted approach is particularly relevant for a clinical audience, as it offers a potential new treatment modality for a patient population that may have exhausted other standard-of-care options. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of HER2-Positive Breast Cancer.
- IBI354: Innovent Biologics
IBI354 is an innovative HER2-targeted antibody–drug conjugate developed using Innovent’s proprietary SoloTx® ADC platform. Based on this platform, Innovent is promoting clinical trial studies multiple self-developed ADC molecules, which have shown promising safety and efficacy signals. With a drug-to-antibody ratio (DAR) of 8, IBI354 delivers a high payload of effective drugs to tumors. The highly hydrophilic linker design contributes to its excellent biophysical and pharmacokinetic (PK) properties, while the hydrophobic payload enhances its bystander effect, targeting adjacent antigen-low or negative tumor cells. IBI354 exhibits extremely low exposure of free toxin in circulation and has an ideal safety profile based on pre-clinical and clinical studies. IBI354 has demonstrated remarkable anti-tumor activity in various tumor-bearing mice models, particularly in those resistant to HER2-targeted therapies and in metastatic tumors Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of HER2-Positive Breast Cancer.
- BB-1701: Eisai Co., Ltd. / Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
BB-1701 is a novel antibody–drug conjugate (ADC) designed to target and cause cytotoxicity to cancer cells that overexpress the HER2 protein. It is composed of an anti-HER2 antibody linked to a cytotoxic payload of eribulin, a synthetic analog of the marine macrolide halichondrin B. The conjugation of the eribulin payload to the antibody is achieved through a maleimido-PEG2-valine-citrulline-p-aminobenzylcarbamyl linker. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of HER2-Positive Breast Cancer.
- HLX22: Shanghai Henlius Biotech
HLX22 is a novel anti-HER2 monoclonal antibody that targets the HER2 extracellular subdomain IV. Its molecular design allows the agent to bind simultaneously to HER2 dimers on the surface of tumor cells. By promoting the internalization and degradation of these HER2 dimers, HLX22 enhances antitumor activity and addresses mechanisms of resistance that may limit the efficacy of existing HER2-targeted therapies. Currently, the drug is being evaluated in the Phase II/III stage of its development for the treatment of HER2-Positive Breast Cancer.
- ELVN-002: Enliven Therapeutics
ELVN-002, is a potent, highly selective, central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. The overexpression, amplification or mutation of HER2 is closely associated with aggressive forms of solid cancers, including breast cancer (BRC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and several others. ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities. Additionally, ELVN-002 is specifically designed to enable rational combination therapies, which will be important for the treatment of patients with metastatic HER2 overexpressing and amplified cancers. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of HER2-Positive Breast Cancer.
The HER2 Positive Breast Cancer Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Positive Breast Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Positive Breast Cancer Treatment.
- HER2 Positive Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- HER2 Positive Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Positive Breast Cancer market
Explore groundbreaking therapies and clinical trials in the HER2 Positive Breast Cancer Pipeline @ New HER2 Positive Breast Cancer Drugs
HER2 Positive Breast Cancer Companies
BioNTech, Innovent Biologics, Shanghai Henlius Biotech, Eisai Co., Ltd., Bliss Biopharmaceutical (Hangzhou) Co., Ltd., EMUXA Biotechnology, CSPC ZhongQi Pharmaceutical Technology, Johnson and Johnson, Novartis Pharmaceuticals, F. Hoffmann-La Roche Ltd, Novartis AG, Jiangsu HengRui Medicine Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Jazz Pharmaceuticals, Inc., Zymeworks Inc., Enliven Therapeutics, Mersana Therapeutics, Iambic Therapeutics, Inc., Alteogen, Inc., and GeneQuantum Healthcare (Suzhou) Co., Ltd and others.
HER2 Positive Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
HER2 Positive Breast Cancer Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Download DelveInsight’s latest report to gain strategic insights into upcoming therapies @ HER2 Positive Breast Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the HER2 Positive Breast Cancer Pipeline Report
- Coverage- Global
- HER2 Positive Breast Cancer Companies- BioNTech, Innovent Biologics, Shanghai Henlius Biotech, Eisai Co., Ltd., Bliss Biopharmaceutical (Hangzhou) Co., Ltd., EMUXA Biotechnology, CSPC ZhongQi Pharmaceutical Technology, Johnson and Johnson, Novartis Pharmaceuticals, F. Hoffmann-La Roche Ltd, Novartis AG, Jiangsu HengRui Medicine Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Jazz Pharmaceuticals, Inc., Zymeworks Inc., Enliven Therapeutics, Mersana Therapeutics, Iambic Therapeutics, Inc., Alteogen, Inc., and GeneQuantum Healthcare (Suzhou) Co., Ltd and others.
- HER2 Positive Breast Cancer Pipeline Therapies- Trastuzumab, Paclitaxel, Zanidatamab, Letrozole, Tamoxifen, PTC+Pertuzumab, FEC-T+Pertuzumab, SHR-A1811, Pyrotinib and others.
- HER2 Positive Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- HER2 Positive Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find out in DelveInsight’s exclusive HER2 Positive Breast Cancer Pipeline Report @ HER2 Positive Breast Cancer Emerging Drugs and Major Companies
Table of Contents
- Introduction
- Executive Summary
- HER2 Positive Breast Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- HER2 Positive Breast Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Trastuzumab Pamirtecan (BNT-323): BioNTech
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- BB-1701: Eisai Co., Ltd. / Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- ELVN-002: Enliven Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- HER2 Positive Breast Cancer Key Companies
- HER2 Positive Breast Cancer Key Products
- HER2 Positive Breast Cancer- Unmet Needs
- HER2 Positive Breast Cancer- Market Drivers and Barriers
- HER2 Positive Breast Cancer- Future Perspectives and Conclusion
- HER2 Positive Breast Cancer Analyst Views
- HER2 Positive Breast Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/her2-positive-breast-cancer-pipeline-insight